Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors
Bin Zhang, Zhikun Liu, Shengjin Xia, et al.
European Journal of Medicinal Chemistry (2021) Vol. 216, pp. 113300-113300
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Kunyu Shi, Guan Wang, Junping Pei, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 99
Molecular hybridization: a powerful tool for multitarget drug discovery
Pedro de Sena Murteira Pinheiro, Lucas Silva Franco, Tadeu L. Montagnoli, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 4, pp. 451-470
Closed Access | Times Cited: 35
Carbonic anhydrase IX: An atypical target for innovative therapies in cancer
Roberto Ronca, Claudiu T. Supuran
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 4, pp. 189120-189120
Open Access | Times Cited: 19
Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors
Claudiu T. Supuran
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 12, pp. 1197-1208
Closed Access | Times Cited: 71
Designing strategies, structural activity relationship and biological activity of recently developed nitrogen containing heterocyclic compounds as epidermal growth factor receptor tyrosinase inhibitors
Rohit Pal, Ghanshyam Teli, Gurubasavaraja Swamy Purawarga Matada, et al.
Journal of Molecular Structure (2023) Vol. 1291, pp. 136021-136021
Closed Access | Times Cited: 31
Novel Indole–Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction
Zhikun Liu, Meng Wang, Ri-Zhen Huang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4868-4887
Closed Access | Times Cited: 21
Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present)
Alexandru Șandor, Ioana Ionuţ, Gabriel Marc, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 534-534
Open Access | Times Cited: 21
Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)
Liping Hu, Mengmeng Fan, Shengmin Shi, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113963-113963
Closed Access | Times Cited: 45
Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders
Claudiu T. Supuran
Journal of Enzyme Inhibition and Medicinal Chemistry (2021) Vol. 36, Iss. 1, pp. 1702-1714
Open Access | Times Cited: 42
New 1,3,4‐oxadiazoles linked with the 1,2,3‐triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase
Mohamed A. Mahmoud, Anber F. Mohammed, Ola I. A. Salem, et al.
Archiv der Pharmazie (2022) Vol. 355, Iss. 6
Closed Access | Times Cited: 35
An appraisal of anticancer activity with structure–activity relationship of quinazoline and quinazolinone analogues through EGFR and VEGFR inhibition: A review
Kashif Haider, Subham Das, Alex Joseph, et al.
Drug Development Research (2022) Vol. 83, Iss. 4, pp. 859-890
Closed Access | Times Cited: 34
Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling
Panupong Mahalapbutr, Ronnakorn Leechaisit, Anusit Thongnum, et al.
ACS Omega (2022) Vol. 7, Iss. 21, pp. 17881-17893
Open Access | Times Cited: 29
Advances in synthesis and biological activities of quinazoline scaffold analogues: A review
S.N. Murthy Boddapati, Hari Babu Bollikolla, K. Bhavani, et al.
Arabian Journal of Chemistry (2023) Vol. 16, Iss. 10, pp. 105190-105190
Open Access | Times Cited: 17
Nitrogen‐Containing Heterocyclic Scaffolds as EGFR Inhibitors: Design Approaches, Molecular Docking, and Structure‐Activity Relationships
Rohit Pal, Ghanshyam Teli, Gurubasavaraja Swamy Purawarga Matada, et al.
ChemistrySelect (2023) Vol. 8, Iss. 26
Closed Access | Times Cited: 15
Targeted Cancer Cell Supramolecular Nanoparticles Self-Assembled from Acyclic Cucurbit[n]urils for Combined Chemo/Chemodynamic/Photothermal Therapy
Ya‐Min Li, Lutao Wang, Feijian Xiao, et al.
Colloids and Surfaces A Physicochemical and Engineering Aspects (2025), pp. 136124-136124
Closed Access
X-ray crystallographic and kinetic studies of biguanide containing aryl sulfonamides as Carbonic anhydrase inhibitors
Chiara Baroni, Murat Bozdağ, G. RENZI, et al.
RSC Medicinal Chemistry (2025)
Open Access
Dual targeting carbonic anhydrase inhibitors as promising therapeutic approach: a structural overview
Katia D’Ambrosio, Anna Di Fiore, Emma Langella
Frontiers in Molecular Biosciences (2025) Vol. 12
Open Access
Medicinal chemistry applications of the Dimroth Rearrangement to the synthesis of biologically active compounds
Luca Pozzetti, Maja M Pinhammer, Christopher R. M. Asquith
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117399-117399
Open Access
Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress
Bharti Sharma, Vikram Jeet Singh, Pooja A. Chawla
Bioorganic Chemistry (2021) Vol. 116, pp. 105393-105393
Closed Access | Times Cited: 38
Design, Synthesis, and Antiproliferative Activity of New 5-Chloro-indole-2-carboxylate and Pyrrolo[3,4-b]indol-3-one Derivatives as Potent Inhibitors of EGFRT790M/BRAFV600E Pathways
Lamya H. Al-Wahaibi, Anber F. Mohammed, Mostafa Abdelrahman, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1269-1269
Open Access | Times Cited: 14
A Medicinal Chemist’s Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents
Bhupender Nehra, Bijo Mathew, Pooja A. Chawla
Current Topics in Medicinal Chemistry (2022) Vol. 22, Iss. 6, pp. 493-528
Closed Access | Times Cited: 19
Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of Cancer: A Review
Aziz Unnisa, Ananda Kumar Chettupalli, Talib Hussain, et al.
Anti-Cancer Agents in Medicinal Chemistry (2022) Vol. 22, Iss. 20, pp. 3370-3381
Closed Access | Times Cited: 19
Design, synthesis, apoptotic, and antiproliferative effects of 5-chloro-3- (2-methoxyvinyl)-indole-2-carboxamides and pyrido[3,4-b]indol-1-ones as potent EGFR WT/ EGFR T790M inhibitors
Lamya H. Al-Wahaibi, Anber F. Mohammed, Fatema El-Zahraa S. Abdel Rahman, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 11
Antitumor activity and mechanisms of dual EGFR/DNA-targeting strategy for the treatment of lung cancer with EGFRL858R/T790M mutation
Lumei Dai, Feng Qin, Yuying Xie, et al.
Bioorganic Chemistry (2023) Vol. 135, pp. 106510-106510
Closed Access | Times Cited: 10
Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors
Mohammed Hawash
Cells (2024) Vol. 13, Iss. 19, pp. 1656-1656
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top